New drug trial aims to stop Alzheimer's before it starts

NCT ID NCT07399171

Summary

This study is testing whether an investigational drug called HT-4253 can prevent Alzheimer's disease in people who carry a specific genetic risk factor (APOE4) and show early signs of brain changes. About 112 participants, aged 50-75 and without an Alzheimer's diagnosis, will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug can lower a blood test score that indicates a high risk of developing Alzheimer's brain plaques.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Abu Dhabi

    Abu Dhabi, United Arab Emirates

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.